General Atomics
With Two Protector RPAs in the UK, GA-ASI Has Delivered a Total of 10 Protectors to RAF; First Four Cadres of RAF Aircrew Complete Training at FTTC
SAN DIEGO, CA / ACCESSWIRE / July 22, 2024 / The United Kingdom's Royal Air Force (RAF) now has two Protector RG Mk1 Remotely Piloted Aircraft (RPA) operating at RAF Waddington. The second Protector has started its ground trial at RAF Station Waddington with first flight expected in August. Protector is based on the MQ-9B SkyGuardian® RPA developed by General Atomics Aeronautical Systems, Inc. (GA-ASI), and is specially configured for the RAF. The RAF has taken delivery of 10 of their total order of 16 Protectors from GA-ASI, with eight aircraft currently undergoing RAF crew training, test, and evaluation in the United States.
To view this piece of content from cdn.nwe.io, please give your consent at the top of this page."We're thrilled to see a second Protector operating at Waddington," said Chris Dusseault, GA-ASI's vice president of MQ-9B in Europe. "The Royal Air Force is a great partner for GA-ASI, and we look forward to additional MQ-9B aircraft operating in the U.K. and more broadly across Europe."
Simon Holford, Uncrewed Air Systems Delivery Team Leader at Defence Equipment & Support, said: "Seeing delivery and assembly of the second Protector aircraft in the UK is yet another measure of the significant progress on this project and testament to the hard work of everyone involved. Together with the three aircraft we have already taken delivery of in the U.S. (which remain in the U.S. for use in trials and/or training), we have now taken delivery of five of the 16 aircraft we have ordered."
Officer Commanding 31 Sqn, Wing Commander Maccoll, said, "I'm delighted to see another RAF Protector assembled at RAF Waddington, thanks to the hard work of our Programme team, Defence partners, contractors, and the skill of 31 Squadron personnel. This summer, Protector will undertake further test and evaluation and we expect more aircraft arrivals before the end of the year. "
In another program milestone, the first of four cadres of RAF aircrew completed training on April 29, 2024, at GA-ASI's Flight Test and Training Center (FTTC) in Grand Forks, North Dakota. The GA-ASI training involved RAF Operational Conversion Units (OCUs), which are comprised of eight crews, including pilots, sensor operators (SOs), and mission intelligence coordinators (MICs) from 31, 54, or 56 Squadrons.
The scope of the training is focused on foundational skills required to operate the Protector air vehicle and its equipment, including the Multi-Spectral Targeting System (MTS), Synthetic Aperture Radar (SAR), Mission Intelligence Station (MIS), and System for Tasking and Real-Time Exploitation (STARE). Training involves building solid foundations for both normal and emergency operations in Intelligence, Surveillance, and Reconnaissance (ISR) systems, instrument flying, and Automatic Takeoff and Landing Capability (ATLC).
With the completion of the Protector Technicians course at GA-ASI facilities in Southern California on May 16, 2024, Number 31 Squadron now has another 21 qualified maintainers. As part of their training course, the RAF maintainers were able to directly support the training flights for their aircrew counterparts who were completing the live flying element of their Operational Conversion course from North Dakota.
MQ-9B is GA-ASI's next-generation RPA System (RPAS), delivering exceptionally long endurance and range, with auto takeoff and landing under SATCOM-only control, and will be able to operate in unsegregated airspace using the GA-ASI-developed Detect and Avoid system. In addition to the RAF, contracts have been signed with Belgium, Canada, Taiwan and the U.S. Air Force in support of the Special Operations Command. The Japan Coast Guard is currently operating the MQ-9B for maritime operations, which the Japan Maritime Self-Defense Force (JMSDF) also selected for its Medium-Altitude, Long-Endurance (MALE) Remotely Piloted Aircraft System Trial Operation Project. MQ-9B has additionally supported various U.S. Navy exercises, including Northern Edge, Integrated Battle Problem, and Group Sail.
About GA-ASI
General Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable RPA systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent situational awareness. The company also produces a variety of sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas.
For more information, visit www.ga-asi.com.
Avenger, Lynx, Predator, SeaGuardian, and SkyGuardian are registered trademarks of General Atomics Aeronautical Systems, Inc.
# # #
Contact Information
GA-ASI Media Relations
asi-mediarelations@ga-asi.com
SOURCE: General Atomics Aeronautical Systems, Inc.
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESSWIRE
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
Loar Announces Pricing of Upsized Public Offering10.12.2024 23:40:00 CET | Press release
WHITE PLAINS, NY / ACCESSWIRE / December 10, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar"), announced today the pricing of its upsized public offering of 5,750,000 shares of its common stock, including 1,897,500 shares offered by certain stockholders and 3,852,500 shares offered by Loar at $85.00 per share. The selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 862,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on December 12, 2024, subject to customary closing conditions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any
PHYLA Announces a Series of International Collaborations With the University of Bradford and UPM and a Significant Government-Supported Land Regeneration Project in the Gambia10.12.2024 14:00:00 CET | Press release
LONDON, UK PHYLA and the University of Bradford join forces to develop marketable compounds, cosmetics and superfood products from the pongamia plant PHYLA has entered into a commercial agreement with the University of Bradford to develop marketable bio-compounds for cosmetics and superfood products derived from the pongamia (oil tree) plant which are cultivated in PHYLA's land regeneration projects. The partnership aims to leverage PHYLA's existing IP by applying specific extraction technologies which maximise the yield and value of bio-compounds and other plant-based products. Phyla's Pongamia Pods Phyla's high-density pongamia pod cluster Professor Anant Paradkar, Director of The Centre for Pharmaceutical Engineering Science (CPES) at the University of Bradford, commented: "We are thrilled to collaborate with PHYLA to advance the development of plant-based products. Our Centre has a long-standing commitment to green and sustainable extraction technologies, and this partnership align
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections10.12.2024 07:30:00 CET | Press release
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites. RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular thera
Young Girl Discovers a 3,500-year-old Egyptian Amulet9.12.2024 07:40:00 CET | Press release
During a family trip near an archaeological site in Hod Hasharon, 12-year-old Dafna Filshteiner found an ancient scarab. LONDON, UK / ACCESSWIRE / December 9, 2024 / Dafna Filshteiner, age 12, was recently hiking below the ancient site of Tel Qana in Hod Hasharon, when suddenly, to her surprise, she discovered an unusual find a beetle-like stone used as an Egyptian amulet about 3,500 years ago. "I was looking down at the ground to find porcupine needles and smooth pebbles," she says. "And suddenly I picked up an interesting stone. I showed it to my mother, and she said it was just an ordinary stone or a bead. But then I saw a decoration and stubbornly insisted it was more than that, so we searched on the Internet. There, we identified more photos of stones similar to what we had found. We realized that it was something special and immediately called the Antiquities Authority." The family turned to Mor Wiesel, an archaeologist at the Israel Antiquities Authority, who thanked Dafna and h
Loar Announces Launch of Public Offering9.12.2024 06:30:00 CET | Press release
WHITE PLAINS, NY / ACCESSWIRE / December 9, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has launched the roadshow for the public offering of 4,750,000 shares of its common stock, including 1,583,333 shares offered by certain stockholders and 3,166,667 shares offered by Loar. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 712,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any exercise by the underwriters of their option to purchase additional shares. Jefferies and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom